The global market for Intranasal Drug and Vaccine Delivery was worth USD 9.1 billion in 2022 and is anticipated to grow to USD 19.6 billion in 2032, with a CAGR of 8.9% during the forecast period. The primary drivers of this growth include the increasing prevalence of chronic diseases such as asthma, diabetes, and Chronic Obstructive Pulmonary Disease (COPD), as well as R&D activities in...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian